Epilepsy Research

A0081096

Study Overview

A prospective, randomized, 12-week, controlled study of visual field change in subjects with partial seizures receiving pregabalin or placebo.

Sponsor

Pfizer, Inc.

Phase of Development

Phase IV

Study Duration

15 weeks

Enrollment Status

Open

Principal Investigator

Joanne B. Rogin, MD

 

SP0982/EP0012

Study Overview

A double-blind, randomized, placebo-controlled, parallel-group, adjunctive therapy for uncontrolled primary generalized tonic-clonic seizures in subjects with idiopathic generalized epilepsy.

Sponsor

UCB Biosciences, Inc.

Phase of Development

Phase III

Study Duration

36 weeks

Enrollment Status

Open

Principal Investigator

Joanne B. Rogin, MD

 

1042-0603/1042-0604

Study Overview

A multicenter, double-blind, randomized, placebo-controlled trial to determine the efficacy and safety of ganaxolone as adjunctive therapy for adults with drug-resistant partial-onset seizures followed by long-term open-label treatment.

Sponsor

Marinus Pharmaceuticals, Inc.

Phase of Development

Phase III

Study Duration

Cohort 1 – 67 weeks

Cohort 2 – 76 weeks

Enrollment Status

Closed

Principal Investigator

Joanne B. Rogin, MD

 

N01379

Study Overview

An open-label, multi-center, follow-up study to evaluate the long-term safety and efficacy of brivaracetam used as adjunctive treatment in subjects aged 16 years or older with epilepsy.

Sponsor

UCB Biosciences, Inc.

Phase of Development

Phase III

Study Duration

2 years

Enrollment Status

Closed

Principal Investigator

Joanne B. Rogin, MD

 

SEP093-451

Study Overview

An ex-vivo study to evaluate serum free thyroxine (FT4) and free triiodothyronine (FT3) measurements using equilibrium dialysis (ED) and automated kit assay for subjects treated with eslicarbazepine acetate (ESL).

Sponsor

Sunovion Pharmaceuticals, Inc.

Phase of Development

Phase IV

Study Duration

1 Visit

Enrollment Status

Closed

Principal Investigator

Joanne B. Rogin, MD

 

If you have any questions about participation or know anyone that may be interested, please contact Louis Thao at 763-302-4135 or louis.thao@mpls-clinic.com.

Important Information:

A description of all the clinical trials stated above are available on https://clinicaltrials.gov/, as required by U.S. Law.

All epilepsy clinical trials being conducted at the Minneapolis Clinic of Neurology are approved by an independent ethics committee called an Institutional Review Board (IRB).  An IRB is a type of committee used in research in the United States that has been formally designated to approve, monitor, and review biomedical and behavioral research involving human subjects.  The purpose of the IRB is to assure that appropriate steps are taken to protect the rights and welfare of human subjects participating in a research study.